PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy

被引：0

作者：

Steiniche, T. ^{[1
]}

Marsico, M. A. ^{[2
]}

Siegel, A. B. ^{[3
]}

Gronbaek, H. ^{[1
]}

Ha, S. ^{[4
]}

Hong, J. Y. ^{[4
]}

Paik, Y-H. ^{[4
]}

Georgsen, J. ^{[5
]}

Pommergaard, H-C. L. ^{[6
]}

Ladekarl, M. ^{[7
]}

Webber, A. ^{[8
]}

Liu, X. ^{[9
]}

Kachurak, A. ^{[2
]}

Skaarup, K. ^{[10
]}

Lee, J. ^{[4
]}

Lim, H. Y. ^{[4
]}

机构：

[1] Aarhus Univ Hosp, Pathol, Aarhus C, Denmark

[2] Merck & Co Inc, Upper Gwynedd Site, Pharmacoepidemiol, N Wales, PA USA

[3] Merck & Co Inc, Oncol Clin Res, Rahway, NJ USA

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Internal Med, Seoul, South Korea

[5] Aarhus Univ Hosp, Pathol, Aarhus, Denmark

[6] Copenhagen Univ Hosp, Dept Surg & Transplantat, Copenhagen, Denmark

[7] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark

[8] Merck & Co Inc, Oncol Early Dev, West Point, NY USA

[9] Merck & Co Inc, CHN Teg Planning & Res Informat, Beijing, Peoples R China

[10] MSD Danmark, Oncol, Copenhagen, Denmark

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1122

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1006P

引用

页码：S697 / S697

页数：1

共 50 条

[1] Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression
Yang, Xiaobo
Shi, Junping
Chen, Xiaoqian
Jiang, Yan
Zhao, Haitao
ONCOLOGIST, 2020, 25 (06): : 470 - 474
[2] Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies
Thomas, Sean D.
Jeong, Ah-Reum
Sakowski, Patrick J.
Sokol, Ethan S.
Kurzrock, Razelle
Goodman, Aaron M.
BLOOD, 2020, 136
[3] Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
Peters, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S74 - S74
[4] Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.
George, Thomas J.
Frampton, Garrett Michael
Sun, James
Gowen, Kyle
Kennedy, Mark
Greenbowe, Joel R.
Schrock, Alexa Betzig
Ali, Siraj Mahamed
Klempner, Samuel Jacob
Flezel, Aram F.
Ross, Jeffrey S.
Stephens, Phil
Miller, Vincent A.
Fabrizio, David
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies
Jeong, Ah-Reum
Trando, Aaron H.
Thomas, Sean D.
Riviere, Paul
Sakowski, Patrick J.
Sokol, Ethan S.
Goodman, Aaron M.
Kurzrock, Razelle
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[6] Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Zhu, Jason
Armstrong, Andrew J.
Friedlander, Terence W.
Kim, Won
Pal, Sumanta K.
George, Daniel J.
Zhang, Tian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[7] PD-L1 expression on circulating tumor cells in patients with hepatocellular carcinoma
Kim, Hee Yeon
Kim, Chang Wook
Kim, Sungkeun
Kim, Ji Young
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 409 - 409
[8] Clinicopathological characteristics and mutational profile of PD-L1 positive hepatocellular carcinoma
Nishida, Naoshi
Kudo, Masatoshi
HEPATOLOGY, 2017, 66 : 87A - 87A
[9] Characterization of tumor mutation burden, PD-L1 and hepatitis B virus in Chinese hepatocellular carcinoma patients.
Xu, Junjie
Liang, Xiao
Liu, Lingxiang
Mou, Haibo
Wan, Zhe
Jiang, Shi
Yang, Zhe
Zeng, Daobing
Chen, Xiaoqian
Shi, Junping
Yao, Ming
Chen, Zhonghai
Wang, Kai
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
Bellmunt, J.
Mullane, S. A.
Werner, L.
Fay, A. P.
Callea, M.
Leow, J. J.
Taplin, M. E.
Choueiri, T. K.
Hodi, F. S.
Freeman, G. J.
Signoretti, S.
ANNALS OF ONCOLOGY, 2015, 26 (04) : 812 - 817

← 1 2 3 4 5 →